Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group

Jones, Glenn; Kacinski, Barry M.; Wilson, Lynn D.; Willemze, Rein; Spittle, Margaret F.; Hohenberg, G; Handl-Zeller, L; Trautinger, Franz; Knobler, Robert

doi:10.1067/mjd.2002.123482

Cited by 194 publications

(149 citation statements)

References 19 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…The concise treatment algorithm provided in Fig. 2 is consistent with published treatment guidelines and expert opinion [199][200][201][202][203][204].…”

Section: Treatment Of Advanced-stage Mf/ss Overviewsupporting

confidence: 73%

“…Therefore, patients with limited-stage disease who require therapy are best approached with skin-directed therapies, usually under the direction of a dermatologist and/or radiation oncologist. Excellent reviews, and treatment guidelines, are available [199][200][201][202][203][204]. Consequently, management of limited-stage disease will be summarized only briefly.…”

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

“…The concise treatment algorithm provided in Fig. 2 is consistent with published treatment guidelines and expert opinion [199][200][201][202][203][204].…”

Section: Treatment Of Advanced-stage Mf/ss Overviewsupporting

confidence: 73%

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

show abstract

“…3,7,16 Use of TSEB has been extensively reviewed and consensus guidelines for the use of TSEB in MF have been published. 42,43 The total treatment dose is usually 30-36 Gy over 8-10 weeks, and electrons of different energies may be used depending on the required penetration depth. 3,7,16 Patients with MF/SS usually receive TSEB only once, however, repeat treatments following relapse have been reported.…”

Section: 7mentioning

confidence: 99%

“…16,44,45 The EORTC consensus guidelines recommend that additional courses of TSEB should be offered only when other appropriate therapies have failed. 43 …”

Section: 7mentioning

confidence: 99%